Skip to content

US · LFCR · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Lifecore Biomedical, Inc. (LFCR) intrinsic value and stock valuation

$6.39as of 2026-11-21 · Mkt cap 187.92M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lifecore Biomedical, Inc. DCF and intrinsic value

InvestorsCraft values LFCR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LFCR’s statements →

Lifecore Biomedical, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Chaska, MN 55318 lifecore.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$129.5M-4.2% 5y CAGRd
20112025
Net income
-$-30.79M
20112025
Free cash flow
$6.23M
20112025
Total equity
-$-14.2M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$129.5M$128.3M$103.3M$111.3M$100.9M
Operating income-$-1.26M-$-8.84M-$-21.8M-$-11.79M-$-8.82M
Net income-$-30.79M$12M-$-99.56M-$-116.72M-$-32.29M
EPSd-$-823.92K$327.6K-$-3.32M-$-3.96M-$-1.1M
Operating cash flow$12.6M$260K-$-17.44M-$-22.59M$16.5M
Capital expenditure-$-6.34M-$-18.39M-$-21.48M-$-29.94M-$-25.22M
Free cash flow$6.23M-$-18.14M-$-38.92M-$-52.53M-$-8.75M
Total assets$232.2M$254M$253.5M$274.7M$502.9M
Total debt$142.6M$133.6M$112.6M$247.8M$215.9M
Net debt$125.1M$125.1M$93.5M$246.8M$214.7M
Total equity-$-14.2M$11.3M-$-4.23M$87.8M$202.8M
Cash and short-term investments$17.5M$8.46M$19.1M$990K$1.16M
Income statement
20252024202320222021
Revenue$129.5M$128.3M$103.3M$111.3M$100.9M
Cost of revenue$88.9M$86.4M$75.3M$72.2M$61.9M
Gross profit$40.6M$41.9M$28M$39.1M$38.9M
Research and development expenses$8.51M$8.57M$8.74M$7.84M$6.68M
Selling, general and administrative expenses$33.4M$40.5M$39M$34.7M$27.7M
Other expenses$0.00$1.66M$2.08M$8.36M$13.4M
Operating expenses$41.9M$50.7M$49.8M$50.9M$47.8M
Cost and expenses$130.7M$137.1M$125.1M$123.1M$109.7M
Interest income$0.00$0.00$70K$80K$50K
Interest expense$0.00$18.1M$17.7M$15.6M$8.93M
Depreciation and amortization$9.5M$8M$13.2M$18.1M$19.9M
Ebitda$8.24M$35.6M-$-33.17M$12.8M-$-990K
Operating income-$-1.26M-$-8.84M-$-21.8M-$-11.79M-$-8.82M
Total other income/expenses, net-$-28.96M$18.4M-$-42.13M-$-8.9M-$-20.96M
Income before tax-$-30.21M$9.51M-$-63.93M-$-20.69M-$-29.79M
Income tax expense$580K$180K$310K-$-5.21M-$-6.35M
Net income-$-30.79M$12M-$-99.56M-$-116.72M-$-32.29M
Weighted average shares outstanding$33.3M$30.5M$30M$29.5M$29.3M
Weighted average diluted shares outstanding$37.4M$36.7M$30M$29.5M$29.3M
Balance sheet
20252024202320222021
Cash and short-term investments$17.5M$8.46M$19.1M$990K$1.16M
Net receivables$33.8M$31.2M$29M$38.3M$41.4M
Inventory$29.1M$40M$40.8M$36M$63.1M
Total current assets$82.3M$81M$93.9M$116.7M$148.3M
Property, plant and equipment, net$122.3M$149.2M$138.7M$124.2M$137.4M
Goodwill and intangible assets$18.1M$18.1M$18.1M$18.1M$59.6M
Long-term investments$0.00$0.00$0.00$0.00$45.1M
Total non-current assets$149.9M$172.9M$159.7M$158M$354.6M
Total assets$232.2M$254M$253.5M$274.7M$502.9M
Accounts payable$5.84M$16.3M$22.1M$13M$16.3M
Short-term debt$1.33M$4.91M$1.85M$142.6M$30.6M
Deferred revenue$8.66M$2.11M$4.05M$920K$640K
Total current liabilities$23.6M$38.9M$39.3M$176.6M$101.9M
Long-term debt$141.3M$128.7M$110.8M$105.2M$185.3M
Deferred revenue, non-current$0.00$4.7M$2.94M$0.00$0.00
Total non-current liabilities$222.8M$203.8M$218.5M$10.3M$198.3M
Capital lease obligations$6.25M$8.91M$11M$12M$22M
Total liabilities$246.4M$242.7M$257.8M$186.9M$300.1M
Common stock$40K$30K$30K$30K$30K
Retained earnings-$-223.2M-$-166.52M-$-178.54M-$-78.97M$38.6M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-590K-$-1.36M
Total equity-$-14.2M$11.3M-$-4.23M$87.8M$202.8M
Total investments$0.00$0.00$0.00$0.00$45.1M
Total debt$142.6M$133.6M$112.6M$247.8M$215.9M
Net debt$125.1M$125.1M$93.5M$246.8M$214.7M
Cash flow statement
20252024202320222021
Net income-$-30.79M$12M-$-99.56M-$-116.72M-$-32.29M
Depreciation and amortization$9.5M$7.95M$13.2M$18.1M$19.9M
Stock-based compensation$9.72M$6.2M$3.61M$2.61M$3.36M
Change in working capital-$-2.34M-$-3.7M$19.8M-$-3.1M$9.76M
Accounts receivable$2.76M-$-2.39M$10.8M-$-6.14M$5.78M
Inventory$5.5M$860K-$-14.81M-$-2.18M-$-2.82M
Accounts payable$0.00-$-6.68M$16M$9.34M-$-5.98M
Net cash provided by operating activities$12.6M$260K-$-17.44M-$-22.59M$16.5M
Investments in property, plant and equipment-$-6.34M-$-18.39M-$-21.48M-$-29.94M-$-25.22M
Acquisitions, net$0.00$0.00$16.7M$73.5M$0.00
Net cash used for investing activities-$-5.17M-$-18.39M-$-4.81M$80M-$-12.31M
Common stock issued$0.00$0.00$4.82M$0.00$0.00
Common stock repurchased-$-1.94M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-7.59M$7.51M$39.7M-$-57.02M-$-3.42M
Net change in cash-$-200K-$-10.63M$17.5M$350K$740K
Cash at end of period$8.27M$8.46M$19.1M$1.64M$1.29M
Operating cash flow$12.6M$260K-$-17.44M-$-22.59M$16.5M
Capital expenditure-$-6.34M-$-18.39M-$-21.48M-$-29.94M-$-25.22M
Free cash flow$6.23M-$-18.14M-$-38.92M-$-52.53M-$-8.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lifecore Biomedical, Inc.

        Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

        CEO
        Paul Josephs
        Employees
        406
        Beta
        1.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Lifecore Biomedical, Inc. (LFCR)?

        InvestorsCraft does not currently publish an intrinsic value for LFCR. How the IC value is calculated.

        Is LFCR undervalued?

        InvestorsCraft does not publish an undervaluation signal for LFCR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.